InkKulture Numbing

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: InkKulture Numbing
Generic name: LIDOCAINE HCL
Manufacturer: Prodigy Media Inc
Product type: HUMAN OTC DRUG
SPL set ID: 85a64315-dfa5-4f23-9f61-1cce694ea6bd
SPL ID: 3f025c8a-2267-9e50-e063-6294a90a747e
Version: 1
Effective date: 2025-09-17
Source export date: 2026-09-28
Source partition: 12
Source file: https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 06:26:08

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		InkKulture Numbing	openfda.brand_name
generic name		LIDOCAINE HCL	openfda.generic_name
manufacturer name		Prodigy Media Inc	openfda.manufacturer_name
ndc	package	70171-0022-1	openfda.package_ndc
ndc	product	70171-0022	openfda.product_ndc
ndc11	package	70171002201	derived:openfda.package_ndc
rxcui		1010895	openfda.rxcui
spl id		3f025c8a-2267-9e50-e063-6294a90a747e	id
spl set id		85a64315-dfa5-4f23-9f61-1cce694ea6bd	set_id
unii		V13007Z41A	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings For external use only. Avoid contact with eyes Stop use and ask a doctor if Condition worsens or symptoms persist for more than 7 days Symptoms clear up and occur again within a few days Do not use in large quantities, particularly over raw surfaces or blistered areas. Do not exceed the recommended daily dosage unless directed by a doctor. Do not use On wounds or damaged skin.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.